Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Aberrant NK Receptor Signaling Associated with Large Granular Lymphoycte Leukemia and Primary Pulmonary Hypertension.

P.K. Epling-Burnette, PhD, Xianhong Chen, Junmin Zhou, Fanqi Bai, MD, Sokol Lubomir, MD, Edna Ku, MD, Jeffrey S. Painter, BS, Zou JianXiang, MD, Todd D. Edwards, MD, Djeu Y. Julie, PhD, Moscinski C. Lynn, MD, Thomas P. Loughran, MD, Sheng Wei, MD

Blood (2007) 110 (11): 4704.

https://doi.org/10.1182/blood.V110.11.4704.4704

Published: 2007

Journal Articles

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

Pearlie K. Epling-Burnette, Fanqi Bai, Jeffrey S. Painter, Dana E. Rollison, Helmut R. Salih, Matthias Krusch, JianXiang Zou, Edna Ku, Bin Zhong, David Boulware, Lynn Moscinski, Sheng Wei, Julie Y. Djeu, Alan F. List

Blood (2007) 109 (11): 4816–4824.

https://doi.org/10.1182/blood-2006-07-035519

Published: 2007

Includes: Supplemental data

Journal Articles

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

P.K. Epling-Burnette, PhD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Rollison Dana, PhD, JianXiang Zou, MD, Edna Ku, MD, Bin Zhong, BS, Sheng Wei, MD, Julie Y. Djeu, PhD, Alan F. List, MD

Blood (2006) 108 (11): 2651.

https://doi.org/10.1182/blood.V108.11.2651.2651

Published: 2006

Journal Articles

Lenalidomide (CC5013, Revlimid®) Promotes T Helper-1 Function Bias and Increases Responsiveness to Autologous Bone Marrow Antigens in Myelodysplastic Syndrome (MDS).

Edna Ku, MD, PhD, JianXiang Zou, MD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2006) 108 (11): 2659.

https://doi.org/10.1182/blood.V108.11.2659.2659

Published: 2006

Journal Articles

Lenalidomide (CC5013, Revlimid®) Alters a T Cell Homeostatic Check-Point in Patients with Myelodysplastic Syndrome (MDS).

JianXiang Zou, MD, Edna Ku, MD, PhD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2006) 108 (11): 851.

https://doi.org/10.1182/blood.V108.11.851.851

Published: 2006

Journal Articles

Complex Immunosuppressive Action of Farnesyltransferase Inhibitor (FTI) R115777 (Tipifarnib, Zarnestra®) with Induction of Apoptosis in T Cells from Patients with Large Granular Lymphocyte (LGL) Leukemia.

Fanqi Bai, MD, JianXiang Zou, MD, Jun Yang, MD, Edna Ku, MD,PhD, Sheng Wei, MD, Thomas P. Loughran, MD, P.K. Epling-Burnette, PhD

Blood (2006) 108 (11): 4960.

https://doi.org/10.1182/blood.V108.11.4960.4960

Published: 2006

NARROW

Aberrant NK Receptor Signaling Associated with Large Granular Lymphoycte Leukemia and Primary Pulmonary Hypertension.

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

Lenalidomide (CC5013, Revlimid®) Promotes T Helper-1 Function Bias and Increases Responsiveness to Autologous Bone Marrow Antigens in Myelodysplastic Syndrome (MDS).

Lenalidomide (CC5013, Revlimid®) Alters a T Cell Homeostatic Check-Point in Patients with Myelodysplastic Syndrome (MDS).

Complex Immunosuppressive Action of Farnesyltransferase Inhibitor (FTI) R115777 (Tipifarnib, Zarnestra®) with Induction of Apoptosis in T Cells from Patients with Large Granular Lymphocyte (LGL) Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Aberrant NK Receptor Signaling Associated with Large Granular Lymphoycte Leukemia and Primary Pulmonary Hypertension.

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

Lenalidomide (CC5013, Revlimid®) Promotes T Helper-1 Function Bias and Increases Responsiveness to Autologous Bone Marrow Antigens in Myelodysplastic Syndrome (MDS).

Lenalidomide (CC5013, Revlimid®) Alters a T Cell Homeostatic Check-Point in Patients with Myelodysplastic Syndrome (MDS).

Complex Immunosuppressive Action of Farnesyltransferase Inhibitor (FTI) R115777 (Tipifarnib, Zarnestra®) with Induction of Apoptosis in T Cells from Patients with Large Granular Lymphocyte (LGL) Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only